论文部分内容阅读
背景:联合应用伏立康唑和卡泊芬净作为器官移植患者侵袭性曲霉感染的基础性治疗方法的疗效尚未进行研究。方法:2003年和2005年进行了一项多中心的研究,对移植受者(n=40)给予伏立康唑和卡泊芬净作为侵袭性曲霉感染的基础性治疗,并与1999年和 2002年用两性霉素B脂质体作为基础性治疗的移植患者(n=47)进行对照研究。用曲霉体外检测评价联合治疗的临床疗效。
BACKGROUND: The efficacy of combined use of voriconazole and caspofungin as a primary treatment for invasive Aspergillosis in organ transplant patients has not been studied. METHODS: A multicenter study was conducted in 2003 and 2005 with voriconazole and caspofungin administered to transplant recipients (n = 40) as the underlying treatment for invasive Aspergillus infection and compared with those used in 1999 and 2002 Amphotericin B liposomes as a basis for the treatment of transplant patients (n = 47) control study. Aspergillus in vitro test to evaluate the clinical efficacy of combination therapy.